Sector News

Pharmaceutical research firm SynteractHCR explores sale: sources

April 13, 2016
Life sciences

SynteractHCR Inc, a privately held U.S. contract research organization (CRO), is exploring a sale that could value it at close to $1.5 billion, including debt, according to people familiar with the matter.

A deal would underscore how the CRO industry has benefited in recent years from pharmaceutical companies’ drive to cut costs, reduce clinical trial times and expand their research and development presence around the world.

SynteractHCR’s owner, private equity firm Gryphon Investors, is working with investment bank Wells Fargo & Co (WFC.N) to run an auction for the company, the people said this week.

SynteractHCR, based in Carlsbad, California, has annual earnings before interest, taxes, depreciation and amortization of aground $160 million, the people added, asking not to be identified because the sale process is confidential.

Gryphon Investors, based in San Francisco, and Wells Fargo declined to comment. SynteractHCR did not immediately respond to a request for comment.

SynteractHCR provides outsourced support to pharmaceutical companies, from drug development to marketing. It was created in its current form in 2008 when Gryphon Investors acquired majority ownership of the company and merged it with another company, Vince & Associates Clinical Research. It has since grown further through acquisitions.

The sale process comes as a string of other private equity-owned pharmaceutical services companies explore divesting themselves or initial public offerings. These include InVentiv Health Inc, eResearch Technology Inc and PCI Pharma Services.

By Carl O’Donnell

Spource: Reuters

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach